Showing results (31-40 of 532) with videos related to
Sort By:
Pageof 54
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cellsShujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationMehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.Leukemia & Lymphoma|January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaAlison R Walker, Hongyan Wang, Katherine Walsh, et al.IEEE International Workshop on Genomic Signal Processing and Statistics : [Proceedings]. IEEE International Workshop on Genomic Signal Processing and Statistics|April 10, 2012
A Scalable, Flexible Workflow for MethylCap-Seq Data AnalysisBenjamin Rodriguez, Hok-Hei Tam, David Frankhouser, et al.Methods in Molecular Biology (Clifton, N.J.)|May 18, 2019
Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In VivoYu-Lin Su, Piotr Swiderski, Guido Marcucci, et al.Leukemia & Lymphoma|October 29, 2021
Donor derived leukemia in allogeneic transplantationIbrahim Aldoss, Mary Clark, Guido Marcucci, et al.Current Opinion in Oncology|October 9, 2008
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Peter Paschka, et al.Journal of Pharmaceutical and Biomedical Analysis|September 5, 2012
Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cellsHouda Alachkar, Zhiliang Xie, Guido Marcucci, et al.Leukemia & Lymphoma|September 11, 2013
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemiaRebecca B Klisovic, William Blum, Zhongfa Liu, et al.Leukemia & Lymphoma|February 11, 2020
Phase I study of AR-42 and decitabine in acute myeloid leukemiaSophia G Liva, Christopher C Coss, Jiang Wang, et al.Pageof 54